Osang Healthcare Co.,Ltd (036220.KQ)
KRW 11870.0
(-2.63%)
KRW 11870.0
(-2.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 142.82 Billion KRW | 190.04% |
| 2022 | 48.75 Billion KRW | 729.53% |
| 2021 | -7.74 Billion KRW | -104.84% |
| 2020 | 160.05 Billion KRW | 10671.03% |
| 2019 | -1.51 Billion KRW | -238.51% |
| 2018 | 1.09 Billion KRW | -49.48% |
| 2017 | 2.16 Billion KRW | 7.86% |
| 2016 | 2 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.45 Billion KRW | 14.24% |
| 2024 Q1 | -5.09 Billion KRW | 37.13% |
| 2023 Q1 | 155.23 Billion KRW | 52319.28% |
| 2023 Q4 | -8.1 Billion KRW | 1.45% |
| 2023 Q3 | -8.22 Billion KRW | -429.51% |
| 2023 Q2 | 2.49 Billion KRW | -98.39% |
| 2023 FY | 141.4 Billion KRW | 190.04% |
| 2022 Q2 | 15.72 Billion KRW | -51.67% |
| 2022 FY | 48.75 Billion KRW | 729.53% |
| 2022 Q4 | 296.14 Million KRW | 44.41% |
| 2022 Q3 | 205.07 Million KRW | -98.7% |
| 2022 Q1 | 32.52 Billion KRW | 415.07% |
| 2021 Q3 | 393.43 Million KRW | 0.0% |
| 2021 FY | -7.74 Billion KRW | -104.84% |
| 2021 Q4 | -10.32 Billion KRW | -2724.17% |
| 2020 FY | 160.05 Billion KRW | 10671.03% |
| 2019 FY | -1.51 Billion KRW | -238.51% |
| 2018 FY | 1.09 Billion KRW | -49.48% |
| 2017 FY | 2.16 Billion KRW | 7.86% |
| 2016 FY | 2 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| InBody Co.,Ltd | 44.46 Billion KRW | -221.192% |
| Curexo Inc. | 1.13 Billion KRW | -12479.023% |
| Seegene, Inc. | -30 Billion KRW | 575.954% |
| i-SENS, Inc. | 10.92 Billion KRW | -1206.815% |
| Ray Co., Ltd. | 6.11 Billion KRW | -2234.404% |
| Gencurix Inc. | -12.37 Billion KRW | 1254.07% |
| Sugentech Inc. | -22.74 Billion KRW | 728.035% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | -2042.355% |